Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Capital Leases (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Capital Leases for 5 consecutive years, with $2000.0 as the latest value for Q3 2025.

  • Quarterly Capital Leases fell 83.33% to $2000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Sep 2025, down 83.33% year-over-year, with the annual reading at $19000.0 for FY2023, N/A changed from the prior year.
  • Capital Leases for Q3 2025 was $2000.0 at Actinium Pharmaceuticals, down from $5000.0 in the prior quarter.
  • The five-year high for Capital Leases was $2.3 million in Q2 2022, with the low at $1000.0 in Q3 2022.
  • Average Capital Leases over 5 years is $177428.6, with a median of $9500.0 recorded in 2024.
  • Peak annual rise in Capital Leases hit 11575.0% in 2022, while the deepest fall reached 95.35% in 2022.
  • Over 5 years, Capital Leases stood at $3000.0 in 2021, then tumbled by 66.67% to $1000.0 in 2022, then soared by 1800.0% to $19000.0 in 2023, then plummeted by 36.84% to $12000.0 in 2024, then crashed by 83.33% to $2000.0 in 2025.
  • According to Business Quant data, Capital Leases over the past three periods came in at $2000.0, $5000.0, and $7000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.